CORONAVIRUS RESEARCH HIGHLIGHTS: 1-MINUTE READS
Severely ill people yield 19 powerful antibodies
Scientists have identified a diverse group of antibodies that block the new coronavirus’s ability to infect cells — even when applied in low doses. Researchers analysed the plasma of 5 people with severe cases of COVID-19 and found 19 neutralizing antibodies that prevented SARS-CoV-2 infection in cell samples. A small dose of one of the antibodies protected golden Syrian hamsters (Mesocricetus auratus) from the infection.
Reference: Nature paper
Viral levels could help to target treatment
The amount of viral RNA in the nose and throat of a person infected with the new coronavirus could help clinicians to decide how to treat them. Researchers analysed the viral load in samples taken from 4,172 people infected with SARS-CoV-2, and noticed 2 distinct stages of COVID-19. Early in the disease, people have high viral loads, which tend to decline gradually as the disease progresses. This later stage is typically characterized by inflammation. Viral-load decline could thus be a cue to start treatment with anti-inflammatory drugs. There was no correlation between viral load and the severity of disease.
Reference: arXiv preprint (not peer reviewed)
Get more of Nature’s continuously updated selection of the must-read papers and preprints on COVID-19.
Scientists have identified a diverse group of antibodies that block the new coronavirus’s ability to infect cells — even when applied in low doses. Researchers analysed the plasma of 5 people with severe cases of COVID-19 and found 19 neutralizing antibodies that prevented SARS-CoV-2 infection in cell samples. A small dose of one of the antibodies protected golden Syrian hamsters (Mesocricetus auratus) from the infection.
Reference: Nature paper
Viral levels could help to target treatment
The amount of viral RNA in the nose and throat of a person infected with the new coronavirus could help clinicians to decide how to treat them. Researchers analysed the viral load in samples taken from 4,172 people infected with SARS-CoV-2, and noticed 2 distinct stages of COVID-19. Early in the disease, people have high viral loads, which tend to decline gradually as the disease progresses. This later stage is typically characterized by inflammation. Viral-load decline could thus be a cue to start treatment with anti-inflammatory drugs. There was no correlation between viral load and the severity of disease.
Reference: arXiv preprint (not peer reviewed)
.png)
No hay comentarios:
Publicar un comentario